Synced daily from ClinicalTrials.gov via AACT. Last sync: .
14 Tebentafusp clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Metastatic Uveal Melanoma & Uveal Melanoma) and 2,696 total planned enrollment. 2 Phase 3 Tebentafusp trials and 7 Phase 2 are listed. 10 Tebentafusp clinical trials are actively recruiting at 47 U.S. sites across 24 states. Most recent activity: NCT06246149 (Nov 2032).
Where to Participate: All Tebentafusp Trial Sites in the U.S. (47 sites across 24 states)
Every actively recruiting Tebentafusptrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
14 Tebentafusp clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are actively recruiting participants.
Are Tebentafusp clinical trials recruiting in 2026?
Yes — 10 Tebentafusp trials are actively recruiting in 2026, with 47 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tebentafusp being studied for?
Tebentafusp is being studied for Metastatic Uveal Melanoma, Uveal Melanoma, Clear Cell Sarcoma (CCS), HLA-A*0201 Positive Cells Present, Locally Advanced Unresectable Uveal Melanoma and 8 more. The trials are grouped by indication on this page.
What phase is Tebentafusp in?
Tebentafusp clinical trials span 2 Phase 3, 7 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tebentafusp clinical trials?
The lead sponsor across the most Tebentafusp trials is Immunocore Ltd, with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tebentafuspas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.